COMPANY PROFILE
Endacea, Inc. is an emerging biopharmaceutical company located in Research Triangle Park, North Carolina.
The Company is developing a series of proprietary A1 adenosine receptor (AR)
antagonists as drugs for inflammatory diseases, including asthma and sepsis, and an endotoxin assay as a biomarker for patients at risk of sepsis. Endacea is also interested in developing one or more of its water soluble, orally bioavailable A1 AR antagonists as oral drugs for patients with congestive heart failure and impaired renal function.
The Company's technology also includes patents pertaining to the use of A1 AR antagonists and P2X purinoceptor antagonists to treat ischemia-reperfusion organ injury, sepsis, disorders resulting in fibrosis and sclerosis, including autoimmune diseases and inflammation (e.g. rheumatoid arthritis), immune system disorders including HIV/AIDS, and other indications. In addition, Endacea owns four patents and patent applications pertaining to the diagnosis, imaging, treatment, and prevention of cancer.
The Company has a growing patent estate that includes 14 issued U.S. patents, 12 pending U.S. patent applications, and 18 issued or allowed international patents.
Please browse Endacea's website for more information about
our company and our
science and contact us
with your inquiries.
Copyright © 2001-2008 Endacea, Inc. ENDACEA and the ENDACEA logo are trademarks of Endacea, Inc.
|
